CClinicalTrials.gg
CompletedNCT05281107Updated Mar 16, 2022

Vitamin D Supplementation and PTH Response Among Malaysian Adults

An Early Phase 1 interventional study of Placebo, 500 mg calcium and 600 IU vitamin D + 500 mg calcium in Healthy, sponsored by International Medical University. Completed at 1 site in Malaysia. Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by International Medical University · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 6 years 7 months after the study started (first participant enrolled Jul 2015, registered Feb 2022).
Phase
Early Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

This clinical trial was designed to determine the efficacy of vitamin D supplementation on plasma 25-hydroxyvitamin D [25(OH)D] and intact parathyroid hormone (PTH) concentrations of Malaysian female adults of child-bearing age after daily intake of vitamin D supplements containing either 0 IU, 600 IU, 1200 IU or 4000 IU vitamin D for 16 weeks.

Read the detailed description

After being informed regarding the study protocol and requirements, participants given informed consent were interviewed using a questionnaire for collection of background data and medical history as a screening process. Eligible participants were randomly assigned in a double-blind manner to receive daily 500 mg of calcium with either 0, 600 IU, 1200 IU or 4000 IU vitamin D supplement for 16 weeks. Questionnaires and anthropometric measurements were collected at baseline and post 16 weeks supplementation trial. Primary outcomes of plasma 25(OH)D and intact PTH were measured via fasting intravenous blood samples at baseline and post 16 weeks trial.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

International Medical University is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • three major ethnic groups (Malay, Chinese, Indian)
  • age 20-45 years

Exclusion criteria

Exclusion Criteria:

  • any diseases or conditions that may affect vitamin D metabolism, such as diabetes, cardiovascular diseases, bone diseases, autoimmune diseases, had major gastrointestinal surgery and diagnosed primary hyperparathyroidism
  • medications that might affect vitamin D metabolism, such as insulin, thiazide diuretics, prednisolone, biphosphonates, tamoxifen and phenytoin
  • pregnant and lactating women
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Placebo comparator
    Placebo, 500 mg calcium

    Participants received 500 mg calcium in berry flavoured sachet powder daily for 16 weeks

    Dietary Supplement: Placebo, 500 mg calcium · Dietary Supplement: 600 IU vitamin D + 500 mg calcium · Dietary Supplement: 1200 IU vitamin D + 500 mg calcium · Dietary Supplement: 4000 IU vitamin D + 500 mg calcium

  • Active comparator
    600 IU vitamin D + 500 mg calcium

    Participants received 600 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks

    Dietary Supplement: Placebo, 500 mg calcium · Dietary Supplement: 600 IU vitamin D + 500 mg calcium · Dietary Supplement: 1200 IU vitamin D + 500 mg calcium · Dietary Supplement: 4000 IU vitamin D + 500 mg calcium

  • Active comparator
    1200 IU vitamin D + 500 mg calcium

    Participants received 1200 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks

    Dietary Supplement: Placebo, 500 mg calcium · Dietary Supplement: 600 IU vitamin D + 500 mg calcium · Dietary Supplement: 1200 IU vitamin D + 500 mg calcium · Dietary Supplement: 4000 IU vitamin D + 500 mg calcium

  • Active comparator
    4000 IU vitamin D + 500 mg calcium

    Participants received 4000 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks

    Dietary Supplement: Placebo, 500 mg calcium · Dietary Supplement: 600 IU vitamin D + 500 mg calcium · Dietary Supplement: 1200 IU vitamin D + 500 mg calcium · Dietary Supplement: 4000 IU vitamin D + 500 mg calcium

Interventions

  • Dietary supplementPlacebo, 500 mg calcium

    Berry flavoured sachet powder (500 mg calcium)

  • Dietary supplement600 IU vitamin D + 500 mg calcium

    Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)

  • Dietary supplement1200 IU vitamin D + 500 mg calcium

    Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)

  • Dietary supplement4000 IU vitamin D + 500 mg calcium

    Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)

06

What researchers measure

Primary outcomes

  1. Change from baseline plasma 25-hydroxyvitamin D at week 16

    5ml of fasting blood sample were taken by venepuncture into heparin tubes. Collected blood samples were centrifuged at 4000 rpm for 10 minutes, extracted plasma and stored at -80˚C until sent for analysis

    Time frame: Baseline and week 16

Secondary outcomes

  1. Change from baseline intact parathyroid hormone at week 16

    5ml of fasting blood sample were taken by venepuncture into heparin tubes. Collected blood samples were centrifuged at 4000 rpm for 10 minutes, extracted plasma and stored at -80˚C until sent for analysis

    Time frame: Baseline and week 16

07

Study locations

1 site
  • International Medical University
    Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur 57000, Malaysia
08

References and documents

Study documents

  • Protocol, analysis plan and consent form · Feb 27, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Data cannot be shared publicly because of shared IPs. Data are available from the International Medical University Institutional Data Access (contact via khor.geoklin@gmail.com) for researchers who meet the criteria for access to confidential data

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05281107
Lead sponsor
International Medical University
Responsible party
Melissa Leong En Ying (Principal Investigator, International Medical University) — Principal investigator
First posted
Mar 16, 2022
Start date
Jul 10, 2015
Primary completion
Sep 26, 2016
Completion
Oct 1, 2016
Last update
Mar 16, 2022

Study contacts

Geok Lin Khor
study chair · International Medical University
Megan Chong
study director · International Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion